Gene, Gene Expression and Licensing - Clinical Research Informer

Kite Gains Access to Refuge's Gene Expression Platform in Licensing Deal

BioSpace

OCTOBER 20, 2022

Kite Pharma entered into a global licensing deal with Refuge Biotechnologies to leverage the latter's propriety gene expression plaform and develop potential blood cancer therapies.

Gene Expression

Gene Expression Licensing Licensing Gene

C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. A key natural regulator, NRF2 controls antioxidant genes’ expression.

Development

Development Gene Expression Licensing Licensing

Another Astellas gene therapy hits a safety hurdle

pharmaphorum

JUNE 27, 2022

The safety of Astellas’ gene therapy portfolio has been thrust into the spotlight once again, after the FDA placed a clinical hold on a trial of its Pompe disease candidate AT845. The delivery vector – an AAV8 capsid – is designed to allow gene expression directly in target tissues like skeletal muscle.

Gene Therapy

Gene Therapy Gene Gene Expression Trials

$4.3 million awarded to advance transcription factor drugs

Drug Discovery World

AUGUST 21, 2023

Transcription factors are proteins that control every gene in a person’s genome by binding to DNA and flipping the on/off switches that govern gene expression. Talus Bio was also awarded a $2.0M Talus Bio’s pipeline also includes the first inhibitor blocking a previously undruggable transcription factor that drives chordoma.

Drugs

Drugs Gene Expression Protein Gene

This week in drug discovery (2-6 October)

Drug Discovery World

OCTOBER 6, 2023

In celebration of the Nobel Prize for Medicine going to two of the early proponents of mRNA technology for creating therapeutics, Katalin Karikó and Drew Weissman, this week our round-up highlights the importance of genetics, genomics and gene editing in drug discovery.

Drugs

Drugs Gene Editing Genome Genomics

Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases

pharmaphorum

AUGUST 2, 2021

Ipsen’s new chief executive David Loew pledged to ramp up spending on the company’s pipeline when he took the helm last year, and a flurry of licensing deals in the last few weeks shows that push is starting to gather momentum. Last December, Ipsen said it planned to spend $3.6

Gene Expression

Gene Expression Gene Licensing Licensing

Synthetic biology: Innovating in drug discovery

Drug Discovery World

AUGUST 1, 2023

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue. Evonetix is in a very exciting phase, having recently opened our early access program.

Drugs

Drugs Gene Expression Engineer Gene

Biotech founder arrested in US amid murder-for-hire investigation

pharmaphorum

MAY 26, 2022

Gümrükcü is a specialist in gene expression profiling in stem cells, and has been working on ways to deliver stem cell transplants to treat cancer without the need for high-dose induction chemotherapy to destroy the patient’s bone marrow. .” ” If convicted, they face mandatory life in prison or the death penalty.

Gene Expression

Gene Expression RNA Licensing Licensing

Astellas licenses companion drug for Pompe gene therapy

pharmaphorum

JANUARY 10, 2023

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. The post Astellas licenses companion drug for Pompe gene therapy appeared first on.

Gene Therapy

Gene Therapy Gene Licensing Licensing

Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata

XTalks

JUNE 17, 2022

Olumiant is a Janus kinase (JAK) inhibitor that was first discovered by Incyte and then licensed to Eli Lilly. It blocks the activity of JAK1 and JAK2 to interfere with the JAK-STAT signaling pathway to dampen the production of inflammatory cytokines through the modulation of gene expression.

FDA Approval

FDA Approval Gene Expression Cosmetics Trials

Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing

Licensing Licensing Marketing Gene Expression

Cash round sets up trial of InteRNA’s microRNA for cancer

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells. Regulus meanwhile remains a microRNA player, but has suffered a number of setbacks.

Trials

Trials Gene Silencing RNA Gene Expression

Tezepelumab granted Priority Review by U.S. FDA

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. Amgen (NASDAQ:AMGN) announced that the U.S. EMJ Allergy Immunol.

Allergies

Allergies Trials In-Vivo Medicine

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

NOVEMBER 9, 2020

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. EMJ Allergy Immunol. 2018; 3: 60-9. 14 Peters MC, Mekonnen ZK, Yuan S, et al. J Allergy Clin Immunol. 15 Fahy JV.

Trials

Trials Production Sales Manufacturing

Clinical Research Informer

Kite Gains Access to Refuge's Gene Expression Platform in Licensing Deal

C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy

Trending Sources

Another Astellas gene therapy hits a safety hurdle

$4.3 million awarded to advance transcription factor drugs

This week in drug discovery (2-6 October)

Ipsen forges $1bn alliance with Exicure on neurodegenerative diseases

Synthetic biology: Innovating in drug discovery

Biotech founder arrested in US amid murder-for-hire investigation

Astellas licenses companion drug for Pompe gene therapy

Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata

Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China

Cash round sets up trial of InteRNA’s microRNA for cancer

Tezepelumab granted Priority Review by U.S. FDA

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

Stay Connected